Journal article
Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response
AJ Walker, M Mohebbi, M Maes, M Berk, K Walder, CC Bortolasci, ZS Liu, CH Ng, MM Ashton, L Berk, AB Singh, GS Malhi, OM Dean
Brain Behavior and Immunity Health | ELSEVIER | Published : 2023
Abstract
Background: Adjunctive minocycline shows promise in treating affective and psychotic disorders; however, the therapeutic mechanism remains unclear. Identifying relevant biomarkers may enhance the efficacy of novel adjunctive treatment candidates. We thus investigated the peripheral immune-inflammatory profile in a randomized controlled trial (RCT) of minocycline in major depressive disorder (MDD). Methods: This sub-study investigated serum samples from a RCT evaluating minocycline (200 mg/day, 12 weeks) in addition to treatment as usual for MDD (ACTRN12612000283875). Of the original sample (N = 71), serum assays were conducted in 47 participants (placebo n = 24; minocycline n = 23) targeting..
View full abstractRelated Projects (1)
Grants
Awarded by Deakin University
Funding Acknowledgements
AJW is supported by a Trisno Family Fellowship, funded in part by an NHMRC CRE (1153607) . OMD is supported by a R.D. Wright Biomedical NHMRC Career Development Fellowship (1145634) . MB is supported by a NHMRC Senior Principal Research Fellowship (1156072) . The authors wish to acknowledge the contributions of the Community and Research Network (CARN) in providing consumer insight into the protocol for the original trial. Finally, the authors thank the service providers and the participants for their role in the original trial.